Ex­elix­is li­cens­es small mol­e­cule from In­sil­i­co for $80M up­front; Ver­tex buys GPCR from Septer­na

Ex­elix­is is buy­ing in­to a can­cer drug can­di­date dis­cov­ered by gen­er­a­tive AI from In­sil­i­co Med­i­cine, the two com­pa­nies an­nounced Tues­day.

The Bay Area can­cer com­pa­ny is pay­ing In­sil­i­co $80 mil­lion up­front for ISM3091 — a small mol­e­cule that in­hibits USP1. The en­zyme is an im­por­tant me­di­a­tor of DNA dam­age re­spons­es, and is dys­reg­u­lat­ed in cer­tain can­cers. Ex­elix­is is in­ves­ti­gat­ing the drug for BR­CA-mu­tat­ed tu­mors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER